The usual way a Korean beauty brand reaches American shelves is a long courtship — distributors, buyers, pilot orders, patience. Genome & Company decided to skip the line. The Korean biotech-and-beauty company has taken control of Allbloom, a U.S.-focused K-beauty distributor, buying the pipeline instead of pitching it.
The move
Reported on October 26, the deal has Genome & Company acquiring a 64.46% stake in Allbloom through a wholly owned subsidiary, Bloom Partners, giving it management control. Allbloom is a K-beauty export and distribution firm that handles U.S. sales and logistics for Korean cosmetics brands, with existing relationships at American retailers including Target and MINISO. The purchase price was not disclosed; the 23 billion won figure that circulated is Allbloom's 2025 revenue, not the deal value.
The point of the purchase is a single brand with a problem worth solving: Yuik (styled UIK), Genome & Company's microbiome skincare line, launched in 2021 and sold in the U.S. so far mainly online, via an Amazon brand store opened in 2025. Owning a distributor with shelf relationships is a way to compress the time and cost of getting Yuik from a web listing into physical American retail.
Why now
K-beauty's U.S. moment is crowded. Getting noticed online is one thing; winning durable shelf space in national chains is another, and it is slow for a brand negotiating alone. Buying a distributor that already clears customs, holds inventory and knows the buyers turns a multi-year climb into an integration project.
Why it matters
This is a go-to-market decision expressed as an acquisition. The news hook is not a product; it is the method — an Asian company entering the Americas not by export but by owning the machinery of distribution on the ground. Genome & Company also says it intends to keep Allbloom's existing brands and partners and add new ones, which would make the subsidiary a platform, not just a channel for one line.
What it signals
If it works, expect imitation. The pattern — a Korean house buying or building U.S. distribution rather than renting it — is exactly the pain point that sits between "popular online" and "stocked nationally." It is also the kind of crossing that bcd-W's service side, Key To X and AtoA, exists to read: the real friction of landing in America is rarely the product.
bcd-W angle. A new serum is not a Worldwide story. A Korean company buying the American distributor that will carry it is — because the crossing, not the cream, is the event. This is Asia playing America by owning the shelf logistics instead of begging for the shelf.
FAQ
What did Genome & Company acquire?
A 64.46% controlling stake in Allbloom, a U.S.-focused K-beauty distributor, through its subsidiary Bloom Partners. The purchase price was not disclosed.
Why buy a distributor?
To carry its microbiome skincare brand Yuik from online sales into physical U.S. retail faster, using Allbloom's existing relationships (including Target and MINISO) and its logistics capability.
What was the 23 billion won figure?
That is Allbloom's reported 2025 revenue, not the value of the deal, which was not disclosed.
Sources
Draft — bcd-W News Team. Worldwide runs web only and is not distributed by email. Deal terms, stake, and Allbloom's headquarters city to be re-confirmed against primary sources before publication; the purchase price is undisclosed.
